Health technology assessments in personalized medicine: Illustrations for cost-effectiveness analysis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 4, 2011, Pages 367-369

  Postma, Maarten J ^a   Boersma, Cornelis ^a   Vandijck, Dominique ^b,c,d   Vegter, Stefan ^a   Le, Hoa H ^a   Annemans, Lieven ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d HASSELT UNIVERSITY   (Belgium)

Author keywords

cost effectiveness analysis; health technology assessment; personalized medicine; pharmacogenetics; testing

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL PHARMACOLOGY; COST EFFECTIVENESS ANALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; MEDICAL PRACTICE; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; TOXICITY;

COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 80051775100     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.50     Document Type: Editorial

References (14)

1. Postma MJ. Public health aspects of vaccines in The Netherlands: methodological issues and applications. J. Public Health 16, 267-273 (2008).
2. Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Clin. Ther. 9, 1651-1661 (2010).
3. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287-293 (2007). (Pubitemid 46505879)
4. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22, 481-493 (2004). (Pubitemid 38858292)
5. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis. Value Health 13, 853-856 (2010).
6. Tolley K, Postma MJ. Pharmacoeconomics and market access in Europe: case studies in Scotland and The Netherlands. ISPOR Connections 6(10), 3-6 (2006).
7. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: Stepping forward towards optimal decision rules. Health Econ. 16, 307-317 (2007). (Pubitemid 46431778)
8. Hoomans T, van der Roer N, Severens JL, Delwel GO. Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement(article in Dutch). Ned. Tijdschr. Geneeskd. 154, A958 (2010).
9. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluation of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 26, 569-587 (2008). (Pubitemid 351871553)
10. Vegter S, Jansen E, Postma MJ, Boersma C. Pharmacoeconomic evaluation of pharmacogenetic and genomic screening programs: an update of the literature. Drug Dev. Res. 71, 492-501 (2010).
11. Retèl VP, Hummel MJM, van de Vijver MJ et al. Constructive technology assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics. Int. J. Technol. Assess. Healthcare 25, 73-83 (2009).
12. Polonsky WH, Fisher L, Schikman CH et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated Type 2 diabetes. Diabetes Care 34, 262-267 (2011).
13. Pharmacoeconomic Guidelines Around The World www.ispor.org/PEguidelines/ index.asp
14. EUnetHTA Joint Action - new phase in EUnetHTA development www.eunethta.net